Investigational drug · Phase 2
RMC-035
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Kidney Injury Following Open-Chest Cardiac Surgery.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "RMC-035"
First trial start
2024
Aug 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RMC-035", any sponsor or status.
Conditions studied
As listed on its trial records.
- Kidney Injury Following Open-Chest Cardiac Surgery
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RMC-035" as an intervention, largest first.
- Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac SurgeryPivotal-lookingTerminated
Guard Therapeutics ABIndustry
NCT05126303 · 177 participants · Start Mar 31, 2022 · Primary completion Apr 15, 2023
Drug: RMC-035; Placebo · For: Acute Kidney Injury
Sites: Fort Wayne, Indiana; Lincoln, Nebraska; Rochester, New York · 29 sites in all
- A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac SurgeryPivotal-lookingCompleted
Guard Therapeutics ABIndustry
NCT06475274 · 170 participants · Start Aug 26, 2024 · Primary completion Sep 11, 2025
Drug: RMC-035; Placebo · For: Kidney Injury Following Open-Chest Cardiac Surgery
Sites: Montreal, Canada; Québec, Canada; Saint John, Canada · 19 sites in all
Guard Therapeutics ABIndustry
NCT04829916 · 13 participants · Start Mar 16, 2021 · Primary completion Jul 15, 2021
Drug: RMC-035; Placebo · For: Acute Kidney Injury (AKI)
Sites: Münster, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI.
Marcello M, Schöne LM, Booke H, et al. · Nephrol Dial Transplant 2026
- POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery.
Zarbock A, Strauss C, Laflamme M, et al. · Trials 2025
- Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study.
Nordström JEA, Wennberg LM, Nowak G, et al. · Transplant Direct 2024
- Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.
Zarbock A, Larsson TE, Noiseux N, et al. · EClinicalMedicine 2024
- Therapeutic α-1-microglobulin ameliorates kidney ischemia-reperfusion injury.
Burmakin M, Gilmour PS, Gram M, et al. · Am J Physiol Renal Physiol 2024
- Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics.
Weiss R, Meersch M, Wempe C, et al. · Kidney Int Rep 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.